The present invention relates to a mitochondrial UQCRB mutant cell line expressing the UQCRB mutant protein. The present invention is directed to a novel research method for UQCRB activity evaluation using a novel mitochondrial UQCRB mutant cell line, and provides a method for anticancer activity evaluation, a method for angiogenesis inhibitory activity evaluation, and a method for screening a UQCRB activity inhibitor. In particular, the cell line of the present invention is a novel cell line having cell proliferative and angiogenesis inducing activities, and provides a method for screening an angiogenesis inhibitor or an anticancer material through the UQCRB activity inhibitory mechanism, and thus can be applied in the development of therapeutic agents against angiogenesis or mitochondria-mediated diseases and various cancers.

The present invention provides methods to predict the treatment response of brain tumors such as glioblastoma multiforme to anti-angiogenic therapy based on quantitative perfusion-weighted MRI that can optionally be combined with intra-tumor specific molecular profiling. Since only a subset of brain cancer patients will benefit from anti-angiogenic therapy, identification of this subset is critical so that the effectiveness of the patient's current anti-cancer treatment regimen and the patient's survival likelihood can be increased by the inclusion of an anti-angiogenic agent.

The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.

The technology described herein is directed to methods and assay related to macrophage differentiation and the role of such in pathogenesis.

Polypeptides comprising hybrid VEGF and PDGF sequences are provided. The polypeptides are useful in inhibition of angiogenesis and treatment of diseases characterized by pathologic neovascularization.

The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.

[Problem] To provide a novel nucleic acid aptamer for a vascular endothelial growth factor receptor, said nucleic acid aptamer being useful for the diagnosis and treatment of various diseases associated with VEGFs that can regulate angiogenesis and receptors for the VEGFs, e.g., tumor angiogenesis, diabetic retina and chronic rheumatoid arthritis.

[Solution] A nucleic acid aptamer characterized by comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 5, and also characterized by being capable of bonding to a human VEGF receptor specifically. In a preferred embodiment of the nucleic acid aptamer, a primer recognition sequence, a fluorescent label, or a biotin molecule, an avidin molecule, a streptavidin molecule or other specific binding tag peptide may be linked to the 5- or 3-terminal of the nucleic acid aptamer for the purpose of making it possible to detect the nucleic acid aptamer easily.

A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

The invention relates to a use of an aurantiamide dipepetide derivative in the treatment or prevention of angiogenesis-related diseases. Accordingly, aurantiamide dipeptide derivatives can be used as angiogenesis inhibitor, whereby preventing or treating invasive and metastatic cancer and ocular neovascularization (particularly macular degeneration such as pathological neovascularization of age-related macular degeneration (AMD)).

The disclosure concerns a method for measuring and reporting vascularity in a biological tissue sample. The method generally includes: within a digital image of a tissue section, (i) identifying endothelial cells, lymphatic cells, or a combination thereof; (ii) mapping one or more proximity regions, each of the proximity regions defining an area between detected vessels and a first distance outwardly therefrom; and (iii) calculating one or more of: a vessel proximity score or a hypoxia score, wherein the vessel proximity score relates a composition of objects within the proximity regions, and wherein the hypoxia score relates a composition of tissue within or outside of the proximity regions, respectively.